Christin Glorioso @ 2024 Biomarkers of Aging Conference

Christin Glorioso presents her work at NeuroAge Therapeutics, where she and her team address brain aging through a multi-modal, multi-omic approach powered by AI.
Timestamps
[00:00:42] Brain aging is a program that leads to neurodegenerative diseases that we can reprogram using drugs and lifestyle interventions
[00:01:18] Epidemiology and biology of age-related neurodegenerative conditions
[00:03:15] Targeting the program that creates the hallmarks of brain aging
[00:05:45] Predicting brain biological ages from blood transcripts
[00:06:20] The NeuroAge Test for Brain Aging - a multi-modal, multi-omic predictor
[00:06:52] How to reverse your brain aging
[00:08:46] Identifying and targeting which genes control the rate of brain aging using AI
[00:09:03] Therapeutic pipeline
Christin Glorioso, MD, PhD is a physician-scientist and co-founder and CEO of NeuroAge Therapeutics, a longevity techbio company that is creating therapies to and biomarkers for reprogramming brain aging. She was previously Head of AI of the Stanford spin-out, TeachAids, and Chief Strategist of the Bakar Aging Research Institute. Christin completed her postdoctoral training at MIT and holds an MD and PhD from the University of Pittsburgh and CMU Medical Scientist Training Program. Try NeuroAge's demo at demo.neuroaget...